trending Market Intelligence /marketintelligence/en/news-insights/trending/YS21DTa4Eh4XjaKtC1_-mg2 content esgSubNav
In This List

Regeneron, Sanofi's dupilumab improves esophagus response in phase 2 trial


According to Market Intelligence, December 2022


Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Japan M&A By the Numbers: Q3 2022

Regeneron, Sanofi's dupilumab improves esophagus response in phase 2 trial

Sanofi and Regeneron Pharmaceuticals Inc.'s phase 2 trial of dupilumab showed that the drug improved the ability to swallow versus placebo in adults with active moderate-to-severe eosinophilic esophagitis.

Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.

The main goal of the trial was the change from baseline to week 10 in a patient-reported measure of swallowing difficulty on a 0 to 9 point scale, with 9 indicating more severe symptoms. All patients irrespective of the treatment given had a baseline score of 6.4.

Patients receiving dupilumab showed significant improvement with a score of 3.4 at the end of 10 weeks, as compared to a score of 5.1 reported by patients receiving placebo.

The drug met all secondary endpoints by improving the symptoms and quality of life versus placebo. There were no new significant safety concerns in the trial.

Dupilumab recently received orphan drug designation from the U.S. Food and Drug Administration.

The drug is already approved in the U.S. and the EU for the treatment of moderate-to-severe atopic dermatitis, a type of skin inflammation.